Merrill keeps Adolor at neutral

Adolor Corp. was maintained at a neutral rating by Merrill Lynch analyst Eric Ende on belief that the stock is fairly priced considering the opportunity in opioid-induced bowel dysfunction (OBD) and post-operative ileus (POI). While expectations for both peak OBD sales and sales of a combination pill of Entereg and vicodin are high, there are development and commercial risks to consider. The commercial opportunity for Entereg in OBD may be smaller than the Street expects, based on the analyst's updated model. Shares of the Exton, Pa.-based biopharmaceutical company were down 8 cents, or 0.32%, at $25.04, on volume of 673,614 shares versus the three-month running average of 416,086 shares. (Nasdaq: ADLR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.